Deferoxamine attenuates iron-induced oxidative stress and prevents mitochondrial aggregation and alpha-synuclein translocation in SK-N-SH cells in culture

Dev Neurosci. 2002;24(2-3):143-53. doi: 10.1159/000065700.

Abstract

One of the defining characteristics of neurodegenerative diseases, including Parkinson's disease, is an abnormal accumulation of iron in the affected brain areas. By using SK-N-SH, a dopaminergic cell line, we have found that iron (100-250 microM FeSO(4)) decreased cell viability, increased lipid peroxidation, and the said effects were blocked by deferoxamine (DFO: 10 microM). Furthermore, DFO, in the absence of iron, enhanced the level of adenosine triphosphate (ATP), but caused chromatin condensation and cell death. Morphological studies revealed that iron (50-100 microM) altered mitochondrial morphology, disrupted nuclear membrane, and translocated alpha-synuclein from perinuclear region into the disrupted nucleus. The results of these studies suggest that DFO is able to block and attenuate iron-mediated oxidative stress. However, in the absence of excess iron, DFO itself may have deleterious effects on the morphology and hence integrity of dopaminergic neurons.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adenosine Triphosphate / analysis
  • Cell Survival / drug effects
  • Deferoxamine / pharmacology*
  • Ferric Compounds / antagonists & inhibitors
  • Ferric Compounds / toxicity*
  • Humans
  • Iron Chelating Agents / pharmacology*
  • Lipid Peroxidation / drug effects
  • Mitochondria / drug effects
  • Mitochondria / metabolism
  • Nerve Tissue Proteins / drug effects
  • Nerve Tissue Proteins / metabolism
  • Neuroblastoma / metabolism
  • Oxidative Stress / drug effects
  • Synucleins
  • Tumor Cells, Cultured
  • alpha-Synuclein

Substances

  • Ferric Compounds
  • Iron Chelating Agents
  • Nerve Tissue Proteins
  • SNCA protein, human
  • Synucleins
  • alpha-Synuclein
  • ferric sulfate
  • Adenosine Triphosphate
  • Deferoxamine